June 21, 2019
A Virginia federal judge on Friday combined several class actions accusing Janssen Biotech of monopolizing sales of cancer drug Zytiga and sent them to New Jersey, saying not only does the case belong there but she doesn't want to overcrowd the Old Dominion court's docket.
June 07, 2019
Janssen Biotech told a Virginia federal court that it's fine if several proposed classes want to combine their suits accusing the pharmaceutical company of delaying the entry of a generic version of its prostate cancer drug Zytiga, as long as the case gets moved to New Jersey.
June 03, 2019
Four proposed classes suing Janssen Biotech for allegedly using sham patent litigation to keep a generic version of its prostate cancer drug off the market want a Virginia federal court to consolidate their suits so they can team up against the pharmaceutical giant.